Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-033766
Filing Date
2025-04-10
Accepted
2025-04-10 16:19:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10623
2 EXHIBIT 1 tm2511894d1_ex99-1.htm EX-99.1 4383
  Complete submission text file 0001104659-25-033766.txt   16691
Mailing Address YALELAAN 62 3584 CM UTRECHT DE
Business Address YALELAAN 62 3584 CM UTRECHT DE 31 030 253 8800
Merus N.V. (Subject) CIK: 0001651311 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89510 | Film No.: 25828645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017
Business Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017 646-970-2123
Paradigm Biocapital Advisors LP (Filed by) CIK: 0001855655 (see all company filings)

EIN.: 851451055 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G